Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses pembrolizumab and more value in squamous cell carcinomas or adenocarcinomas ASCO GI 2016
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content